National Psoriasis Foundation Prioritizes PsA with New Program

National Psoriasis Foundation (NPF) has announced plans to launch the largest realignment and expansion of its psoriatic arthritis (PsA) program since the organization began serving this community nearly 20 years ago. The NPF has provided disease-management services and information to people with PsA, which affects as many as 1 in 3 people with psoriasis, the most common autoimmune disease in the country. Despite sharing similarities with rheumatoid arthritis — including painful symptoms and disease prevalence of approximately 1 million people — there are significantly fewer resources for people with PsA than for those with rheumatoid arthritis. To address these disparities, the NPF PsA Project will focus on 4 areas:
• Decreasing the average time of diagnosis of PsA from 4 years to 1 year.
• Helping people with PsA better manage their disease.
• Reducing barriers to healthcare and treatments.
• Improving understanding of PsA symptoms, disease management and impact on patient quality of life among healthcare providers.
“The National Psoriasis Foundation emphasis on psoriatic arthritis will substantially change the lives of millions of people living with PsA and their families, and will give healthcare providers new tools to help us better serve our patients,” explained Philip Mease, MD, chair of the PsA Project Design Committee and rheumatologist at the Swedsh Medical Center and the University of Washington in Seattle. The design committee, comprised of key medical experts in rheumatology and dermatology, PsA researchers and patients, will guide the organization in accomplishing its aggressive goals to better serve its community of people with PsA. “We know that people with psoriatic arthritis require more. That’s why the National Psoriasis Foundation will elevate psoriatic arthritis so we can bring the level of information and services up to par with the exemplary service we offer for psoriasis,” said Randy Beranek, NPF president and CEO.
“We wouldn’t be able to grow our psoriatic arthritis services without the initial investment in this project by our corporate partners AbbVie, Celgene and Janssen Biotech, who join us in our desire to see that people with psoriatic arthritis live well and receive great care,” he said. To support the NPF PsA Project, visit